key: cord-0796353-05qibtt6 authors: Bessen, C.; Plaza-Sirvent, C.; Bhat, J.; Marheinecke, C.; Urlaub, D.; Bonowitz, P.; Busse, S.; Schumann, S.; Vidal Blanco, E.; Skaletz-Rorowski, A.; Brockmeyer, N.; Overheu, O.; Reinacher-Schick, A.; Faissner, S.; Watzl, C.; Pfaender, S.; Potthoff, A.; Schmitz, I. title: Impact of SARS-CoV-2 vaccination on systemic immune responses in people living with HIV date: 2022-04-10 journal: nan DOI: 10.1101/2022.04.08.22273605 sha: 2e9db2c5d3a5205cea40efebcb6f38f7ed7573aa doc_id: 796353 cord_uid: 05qibtt6 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and an ongoing global pandemic. Despite the development of vaccines, which protect healthy people from severe and life-threatening COVID-19, the immunological responses of people with secondary immunodeficiencies to SARS-CoV-2 mRNA vaccines are currently not well understood. Human Immunodeficiency Virus (HIV), causing acquired immunodeficiency syndrome (AIDS), targets CD4+ T helper (Th) cells that orchestrate the immune response. Anti-retroviral therapy suppresses HIV burden and restores Th cell numbers. Here, we investigated the humoral and cellular immune responses elicited by the BTN162b2 vaccine in a cohort of people living with HIV (PLWH), who receive anti-retroviral therapy. While antibody responses in PLWH increased progressively after the first and second vaccination compared to baseline, they were reduced compared to HIV negative study participants (controls). CD8+ T cells exhibited a general activated phenotype and increased effector and effector memory compartments. In contrast, CD4+ Th cell responses exhibited a vaccination-dependent increase and were comparable between PLWH and controls. In line with their reduced humoral response, the correlation between neutralizing antibodies and the CD4+ T cell response was decreased in PLWH compared to healthy controls. Interestingly, CD4+ T cell activation negatively correlated with the CD4 to CD8 ratio, indicating that low CD4 T cell numbers do not necessarily interfere with cellular immune responses. Taken together, our data demonstrate that COVID-19 mRNA vaccination in PLWH results in potent cellular immune responses, but the reduced antibody responses suggest that booster vaccination might be required for preventing disease. Since early 2020, the world is suffering from a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, also known as 2019-nCoV) 1 . Clinical manifestations of coronavirus disease 2019 (COVID- 19) , the disease caused by SARS-CoV-2, diverge from asymptomatic stage or mild influenza-like symptoms to death due to the acute respiratory failure. Most infected patients recover without the need for hospital care, but factors such as age or existence of comorbidities, like diabetes or immunodeficiency, determine the probability to develop severe COVID-19 2, 3 . SARS-CoV-2 infection elicits humoral responses, most importantly antibodies against viral proteins, as well as a wide variety of cellular responses 4, 5, 6, 7, 8, 9, 10 . Among other measures to control the pandemic, vaccination strategies have been implemented to prevent severe COVID-19 11 . In contrast to traditional vaccination strategies, a novel technology of mRNA-based vaccines has been implemented. The novel mRNA-based vaccines deliver in vitro transcribed mRNA molecules encoding for a pathogen antigen, which are encapsulated in lipid nanoparticles 12 . In case of COVID-19 mRNA-based vaccines, the SARS-CoV-2 spike protein, which binds to the human angiotensin-converting enzyme 2 (ACE2) receptor, is translated and presented by antigen-presenting cells, generating a specific immune response 12, 13 . Besides safety and efficacy, studies demonstrated that these vaccines are able to generate a durable response 14, Vaccine safety and efficacy are being stringently monitored during vaccine development and vaccination campaign. Still, the effectiveness of vaccine is not completely clear in patients with immunodeficiency such as human immunodeficiency virus (HIV) infection. Currently, it is poorly understood whether people living with HIV (PLWH) have a higher risk to develop severe COVID- 19 . In initial COVID-19 cohort studies, comparable clinical outcomes were found in the PLWH and HIV-negative individuals 24, 25, 26, 27, 28, 29, 30 . Contrariwise, in other cohort studies, PLWH presented worse outcomes including higher rates of hospitalization and mortality 31, 32, 33, 34, 35 . In addition, an observational study described lower IgG concentration and neutralizing antibody titers correlating with more cases of severe COVID-19 in PLWH 36 . In contrast, a recent work investigating humoral and T cell specific-responses to the SARS-CoV-2 infection revealed that PLWH could mount a persistent immune response comparable to HIV-negative subjects 37 . Additionally, the correlation analysis in the latter study suggested that deviations in the CD4 to CD8 ratio may result in a diminished ability to respond to SARS-CoV-2 infection in the PLWH 37 . Taken together, the current data on SARS-CoV-2 infection and PLWH raises the question whether and how COVID-19 vaccines raise immune responses. Our present study aims to clarify whether immunity elicited by a COVID-19 mRNA vaccine in the PLWH is modulated in comparison to vaccination in HIV-negative people. The study was authorized by the local ethics committee of the Ruhr-University Bochum and 20-6953-bio). Study participants were recruited at the WIR -Walk in Ruhr, Department of Dermatology, Ruhr-University Bochum. We included healthy age-matched HIV-negative All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2022. ; https://doi.org/10.1101/2022.04.08.22273605 doi: medRxiv preprint samples below the detection limit were interpreted as negative and set to 1. The assay was calibrated according to the World Health Organization international standards and values were expressed as binding antibody units (BAU). SARS-CoV-2 pseudoviruses were prepared as described previously 39 . Briefly, sera were 18 hours post infection, firefly luciferase (FLuc) reporter activity was determined as previously described 41 using a CentroXS LB960 (Berthold). The reciprocal antibody dilution causing 50% inhibition of the luciferase reporter was calculated as pseudovirus neutralization dose 50% (PVND50). Detection range is defined to be between 1:20 and 1:2560. PBMCs were thawed in a 37 °C water bath and diluted in 10 ml RPMI 1640 with Glutamine (Capricorn) with 5 % human AB serum (PAN-Biotech) and 5 U/ml Benzonase (Merck/Sigma) and centrifuged at 400 g for 5 min. The pellet was washed with 10 ml thawing medium, resuspended in 5 ml culture medium (RPMI 1640 with Glutamine (Capricorn) plus 5 % human AB serum (PAN-Biotech)) and cells were rested for at least 2 hours. Cell number was determined using 7aminoactinomycin D in a Cytoflex LX (Beckman Coulter). 100 µl per sample were seeded in All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Mann-Whitney or Kruskal-Wallis one-way ANOVA tests were performed to calculate statistical significance using Prism (GraphPad Software v9.2.0, San Diego, CA). The data were imported in R program (v3.6.3). Correlation analysis was performed using "rcorr" function of Hmisc package (v4.4-0) and visualized by "ggscatter" function of ggplot2-based ggpubr package (v0.2.5). Spearman method was used to compute the correlation coefficient (R) and p-value £ 0.05 was considered as significant correlation. Antibody titers were compared by using the Kruskal-Wallis test with Dunn's multiple comparison or Mann-Whitney test. The immune response towards COVID-19 vaccines in patients with severe diseases such as cancer has recently been assessed 42, 43, 44, 45 . However, an in-depth analysis of immune responses in PLWH has not been performed, yet. Therefore, we recruited a cohort of 71 people living with HIV (PLWH) receiving anti-retroviral therapy (ART) (mean age = 46.1 ± 10.9; 62 male and 9 female) and 20 healthy donors (controls; mean age = 39.4 ± 11.9; 8 male and 12 female) to analyze humoral and cellular immune responses after two doses of vaccination. All participants received the BNT162b2 vaccine (Pfizer-BioNTech). Except three participants, all of the PLWH cohort had All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2022. ; https://doi.org/10.1101/2022.04.08.22273605 doi: medRxiv preprint a CD4 count higher than 200 cells/µl before and 3 months after vaccination (mean CD4 count: Table 1 . Blood samples were drawn immediately before the first (T0) and second (T1) vaccination and four to six weeks after the second vaccination (T2) (Fig. 1A) . Fig. 1) . Notably, two donors in the PLWH group had detectable antibody titers already at T0 suggesting that they had a previous asymptomatic SARS-CoV-2 infection ( Supplementary Fig. 1 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2022. ; https://doi.org/10.1101/2022.04.08.22273605 doi: medRxiv preprint Next, we analyzed the capacity of sera to neutralize SARS-CoV-2 infection. To this end, we employed an established pseudovirus assay 39 and determined the neutralization dose against the viral strain first reported in Wuhan, China (referred to hereafter as WT) and Delta SARS-CoV-2 strains. The amounts of neutralizing antibodies were highly reduced in PLWH compared to healthy controls for both, WT (p = 0.0004) and Delta (p <0.0001) SARS-CoV-2 strains (Fig. 1C ). Nearly the same statistically significant correlation was found between anti-RBD antibody response and neutralization capacity against WT SARS-CoV-2 strain in healthy participants (R=0.82, p=3.8e-06) as well as PLWH cohorts (R=0.83, p<2.2e-16) (Fig. 1D ). However, the correlation analyses for anti-RBD antibody and neutralization against SARS-CoV-2 Delta strain were remarkably decreased in PLWH patients (R=0.69, p=1.7e-10) and healthy controls (R=0.84, p=4.5e-06) (Fig. 1E ). The neutralization capacity against WT and Delta strains of SARS-CoV-2 correlated better in PLWH patients (R=0.87, p<2.2e-16) compared to healthy individuals (R=0.76, p=9.5e-05) ( Fig. 1F ), which might be due to the higher number of participants in the PLWH cohort. We conclude that although SARS-CoV-2 vaccination induces antibody responses in PLWH, but the extent of the humoral immune response is reduced compared to healthy controls. Next, we analyzed cellular immune responses towards SARS-CoV-2 vaccination in PLWH and control groups. Here, multi-parameter flow cytometry was employed and the gating strategy is shown in Supplementary Fig. 2 . We started with analyzing the frequencies of T cells and the two major T cell lineages, CD4+ helper and CD8+ cytotoxic cells. We detected no differences in the frequencies of total T cells as marked by CD3 expression between PLWH and the control group ( Fig. 2A) . As expected, the frequency of CD4+ T cells was reduced in PLWH compared to the controls (Fig. 2B) , while the frequency of CD8+ T cells was increased (Fig. 2C) . Accordingly, the ratio of CD4 to CD8 T cells was significantly lower in PLWH compared to the control group (Fig. 2D ). Of note, the frequency of PD-1 expressing CD4+ T cells, a marker associated with an exhausted phenotype, was increased in PLWH compared to controls (Fig. 2E ). The frequency of CD19+ B cells was reduced in PLWH compared to the control group (Fig. 2F ). Within the CD8+ compartment, the naïve CD8+ T cells (CD27+ CD45RA+ CCR7+) were reduced in PLWH compared to controls (Fig. 3A ). In line, naïve CD8+ T cells of PLWH exhibited (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2022. ; https://doi.org/10.1101/2022.04.08.22273605 doi: medRxiv preprint 2 infection in PLWH 37 , we found that ART did not fully reconstitute the T cell compartment in PLWH and that CD8+ T cells exhibit an activated phenotype. (Fig. 5B ). We found a significant anti-correlation between S-peptide antigen-specific CD4 T cells expressing activation All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2022. ; https://doi.org/10.1101/2022.04.08.22273605 doi: medRxiv preprint markers CD154+CD137+ and the ratio of CD4 to CD8 in the PLWH cohort (R=-0.39; p-value=0.0033; Fig. 5C lower scatter plot), which was insignificant in healthy controls (R=-0.31; p-value=0.18; Fig. 5C upper scatter plot). Thus, low CD4+ relative to CD8+ T cell counts are surprisingly associated with better activation of CD4+ T cells. We then measured IFNg and TNFa expression in the CD154 and CD137 co-expressing CD4+ T cells and found a robust increase in single (IFNg or TNFa) or double (IFNg and TNFa) cytokineproducing cells in PLWH after the first and the second vaccination (Fig. 5D-F) . Importantly, the expression of activation markers and cytokines at the T2 time point exhibited no significant differences between PLWH and the control group. Therefore, despite the known reduced frequency of CD4+ T helper cells in PLWH, the antigen-specific responses in the CD4 compartment are comparable between PLWH and control groups. Furthermore, comparable findings were obtained when activated CD4+ T cells that only expressed the activation marker CD154 were analyzed for S-peptide stimulation ( Supplementary Fig. 4B-D) and correlated with neutralization against delta variant (Supplementary Fig. 4E ). In conclusion, while the cellular immune response by CD4+ T cells is surprisingly comparable to the control All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2022. ; https://doi.org/10.1101/2022.04.08.22273605 doi: medRxiv preprint group, the humoral response mediated by antibodies is reduced suggesting that PLWH might be less protected from COVID-19 by vaccination. The occurrence of SARS-CoV-2 in the human population in late 2019 led to a pandemic that is causing a major health care burden worldwide. In an effort to cope with the pandemic, several (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2022. ; https://doi.org/10.1101/2022.04.08.22273605 doi: medRxiv preprint against Delta as compared to the correlation of anti-RBD antibodies versus neutralizing antibodies against the SARS-CoV-2 WT strain. This might indicate an improved immune evasion of the Delta variant and raises concerns about the protection that two doses of mRNA vaccine mount in PLWH against current and upcoming variants of concern of SARS-CoV-2. Our results on the humoral immune response are in agreement with other reports that reported on immunogenicity and safety of COVID-19 vaccines 55, 56, 57 . In contrast, similar antibody responses were reported in a PLWH cohort that received an inactivated SARS-CoV-2 vaccine 58 . Next to antibody titers, we also analyzed cellular immune responses in PLWH upon COVID-19 vaccination by multi-parametric flow cytometry. As expected 59 , we detected a reduced CD4+ to CD8+ T cell ratio and CD8+ T cells exhibited a more activated phenotype. A reduced naïve CD8 compartment and a higher prevalence of effector, effector memory and transitional memory CD8+ T cells was not only observed by conventional flow cytometrical analysis but also by unsupervised t-SNE clustering. Additionally, the activated phenotype of CD8+ T cells prevented the analysis of antigen-specific CD8+ T cell responses since these cells expressed the type I immunity signature cytokines IFNg and TNFa already in the absence of any stimulation in our in vitro cultures. A higher activation and a reduced naïve compartment in PLWH were also observed for CD4+ T cells, again by conventional flow cytometrical analysis and unsupervised clustering using t-SNE. Nevertheless, we were able to analyze antigen-specific CD4+ T cell responses since the expression of cytokines in the absence of any re-stimulating peptides was negligible. Of note, we detected higher responses to the peptide pool containing M and N derived peptides in PLWH after full vaccination as compared to the control group ( Supplementary Fig. 4A ). One explanation could be that a few donors of the PLWH cohort contracted a SARS-CoV-2 infection. Although no case of symptomatic COVID-19 was reported to us during sampling of the PLWH cohort, we indeed All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2022. ; https://doi.org/10.1101/2022.04.08.22273605 doi: medRxiv preprint detected anti-RBD antibodies in two PLWH donors suggesting asymptomatic SARS-CoV-2 infections. An alternative explanation might be that these responses are due to previous exposures to other human corona viruses, which can cause common cold symptoms and might share common epitopes with SARS-CoV-2. More importantly, we detected an increase in the expression of the activation marker CD137 and CD154 as well as in the expression of the cytokines IFNg and TNFa by CD4+ T cells over the time course of vaccination. Notably, the expression of these markers and the frequency of multifunctional T cells, which express both IFNg and TNFa, was similar in PLWH and in the control group. Thus, despite the reduced CD4+ T cell count in the peripheral blood of PLWH, the CD4+ cellular response to COVID-19 vaccination is preserved. Furthermore, we found a positive correlation between the frequency of multifunctional CD4+ T cells (CD4+ CD137+ CD154+ IFNg+ and TNFa+) and neutralizing antibody responses in PLWH. However, the correlation was less pronounced in comparison to the one in healthy controls, and the correlation was lost for multifunctional CD4+ T cells and anti-RBD antibodies. In addition, we found that the CD4 to CD8 ratio negatively correlated with T cell activation, as detected by the presence of CD4+ CD137+ CD154+ cells, in response to antigens derived from the spike protein in PLWH. No such significant correlation was found in the healthy control group. Therefore, a reduction in CD4+ relative to CD8+ T cells appears to result in better T cell activation in PLWH. Moreover, the CD4 to CD8 ratio might be a predictive biomarker for the effectiveness (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2022. ; https://doi.org/10.1101/2022.04.08.22273605 doi: medRxiv preprint we found similar CD4+ T cell responses in PLWH vaccinated with an COVID-19 mRNA vaccine. Whether these differences are due to differences in the viral antigen or due to the different vaccine formulation remains to be tested in future studies. While the CD4+ T cell responses towards spike protein-derived peptides are promising, the reduced antibody responses raise the question whether two doses of mRNA vaccine are sufficient to protect PLWH from COVID-19. Recent evidence suggests that a booster by a third dose of vaccine not only enhances antibody levels, which might decrease over time, but also broadens the antibody-mediated immunity and can protect against variants of concern 66, 67, 68, 69 . Therefore, additional booster vaccinations might be required for PLWH to maintain or to reach full protection from COVID-19. The PLWH participants in our study received well-adjusted anti-retroviral therapy (ART) and had CD4+ T cells counts higher than 200 cells/µl. Whether immune responses upon COVID-19 vaccination correlate with T cell numbers in the peripheral blood awaits the analysis of a larger cohort with more diverse T cell counts. Moreover, we did not test directly for vaccine safety or efficacy since this would be beyond the scope of this study. Nevertheless, no gross adverse effects were reported by the participants of our PLWH cohort. Furthermore, our results suggest that vaccination of PLWH with COVID-19 mRNA vaccines might elicit partial humoral and cellular immune protection. Future studies have to show, whether or not booster vaccination will enhance immune protection, especially against upcoming variants of concern. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2022. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2022. ; https://doi.org/10.1101/2022.04.08.22273605 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2022. ; https://doi.org/10.1101/2022.04.08.22273605 doi: medRxiv preprint 50% (PVND50) is plotted. (D-F) The scatter plots represent correlation analysis between indicated parameters for control and PLWH groups. Black dots are the individual human donors. The regression line is indicated in blue, while gray area is 95% confidence interval region. In the graphs, R is abbreviated for correlation coefficient and p stands for p-value of statistical significance. Statistical significance was calculated by two-tailed Mann-Whitney test: *p < 0.05, ***p < 0.001, ****p < 0.0001. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2022. ; https://doi.org/10.1101/2022.04.08.22273605 doi: medRxiv preprint 0.01, ***p < 0.001, ****p < 0.0001 (PLWH T0, n= 65; PLWH T1, n= 54; PLWH T2, n= 64; Control T2, n= 20). (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2022. ; https://doi.org/10.1101/2022.04.08.22273605 doi: medRxiv preprint T cells for control and PLWH groups. Statistical significance was calculated by Kruskal-Wallis test and Dunn's test for multiple comparisons (a) or two-tailed Mann-Whitney test (b-e): **p < 0.01, ***p < 0.001, ****p < 0.0001 (PLWH T0, n= 65; PLWH T1, n= 54; PLWH T2, n= 64; Control T2, n= 20). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. T2, 4 to 6 weeks after second vaccination; S, spike protein-derived peptide pool. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2022. ; https://doi.org/10.1101/2022.04.08.22273605 doi: medRxiv preprint CD4pos.CD137pos.CD154pos.IFNgpos.TNFapos.Spept ND50_WildType All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2022. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 10, 2022. ; https://doi.org/10.1101/2022.04.08.22273605 doi: medRxiv preprint A pneumonia outbreak associated with a new coronavirus of probable bat origin COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience Factors associated with COVID-19-related death using OpenSAFELY Persistent cellular immunity to SARS-CoV-2 infection Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals Human neutralizing antibodies elicited by SARS-CoV-2 infection Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 Convergent antibody responses to SARS-CoV-2 in convalescent individuals Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting mRNA vaccines for infectious diseases: principles, delivery and clinical translation Cell entry mechanisms of SARS-CoV-2 Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance -VISION Network, 10 States SARS-CoV-2 and HIV coinfection: clinical experience from Rhode Island, United States COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients Outcomes Among HIV-Positive Patients Hospitalized With COVID-19 Clinical Characteristics and Outcomes in People Living With Human Immunodeficiency Virus Hospitalized for Coronavirus Disease C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial Immunological mechanisms of vaccine-induced protection against COVID-19 in humans Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in highrisk occupational population: a randomized, parallel, controlled clinical trial Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1 Immunogenicity and safety of the BNT162b2 COVID-19 mRNA vaccine in PLWH: A monocentric study in Bari, Italy COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity. Vaccines (Basel) Harnessing CD8(+) T Cells Under HIV Antiretroviral Therapy CD4/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in Virologically Suppressed HIV-Infected Patients CD4/CD8 ratio as a predictor of the response to HBV vaccination in HIV-positive patients: A prospective cohort study HIV infection Worsens Age-Associated Defects in Antibody Responses to Influenza Vaccine Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIVinfected individuals HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guerin vaccine Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis We would like to thank all blood donors who participated in this study. We